(MENAFN- GlobeNewsWire - Nasdaq) This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE ...

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.

The hope is that this will be an improvement for the CAR-T treatment landscape. However, this is only possible if it ends up working out through several other studies. Plus, that GLPG5101 and ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis ...

What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T ...

In this interview, Tong Huo discusses the current landscape of CAR-T therapies and the future of CAR-T, including next-generation approaches, gene-editing innovations and applications beyond oncology.

and the broader competitive landscape in cell therapy for autoimmune diseases. Kapoor acknowledges the potential of KYV-101, a CD19-targeting CAR-T cell therapeutic, but remains guarded pending ...

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This report ...

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. It highlights approved CAR-T therapies and late-stage clinical trials that ...